We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.
- Authors
Stump, Kristine L; Lu, Lily D; Dobrzanski, Pawel; Serdikoff, Cynthia; Gingrich, Diane E; Dugan, Ben J; Angeles, Thelma S; Albom, Mark S; Ator, Mark A; Dorsey, Bruce D; Ruggeri, Bruce A; Seavey, Matthew M
- Abstract
Janus kinase 2 (JAK2) is involved in the downstream activation of signal transducer and activator of transcription 3 (STAT3) and STAT5 and is responsible for transducing signals for several proinflammatory cytokines involved in the pathogenesis of rheumatoid arthritis (RA), including interleukin (IL)-6, interferon γ (IFNγ) and IL-12. In this paper, we describe the efficacy profile of CEP-33779, a highly selective, orally active, small-molecule inhibitor of JAK2 evaluated in two mouse models of RA.
- Publication
Arthritis research & therapy, 2011, Vol 13, Issue 2, pR68
- ISSN
1478-6362
- Publication type
Journal Article
- DOI
10.1186/ar3329